How the New Health Economy is Changing PharmaDeclaring that we're in a "New Health Economy," the global consulting firm PwC says life sciences and drug companies are facing multiple new challenges that are turning old business models on their head.Read the rest of this entry »
There are "three pivotal healthcare and pharma industry developments... that pharma companies must confront in 2017," says PwC in an article on the firm's Strategy& site. As Pwc describes them, the three are:
- The year ...
Pharma's 2016 TV Spend Topped $2.2 BillionAnyone who watches TV, especially daytime TV, couldn't help but wonder just what kind of miracle drug Humira must be. Ads for the drug aired more than 69,000 times last year.Read the rest of this entry »
In order of how much its manufacturer, AbbVie spent touting Humira's uses:
- Arthritis -- $173 million
- Crohn's and colitis -- $118 million
- Psoriasis -- $54 million.
Among the top 20 brands advertised on TV, Humira's $344 million ...
More Biotech PhDs Are Starting CompaniesThe boom in biotech funding coupled with the paucity of academic jobs is tempting young scientists to skip post-doc research in favor of heading straight into business.Read the rest of this entry »
The science journal Nature says there's a "vanguard of young biomedical scientists who have started companies instead of taking the conventional academic path and pursuing postdoctoral studies after their PhDs."
Where once investors would only fund companies started by established professors who ...
Pharma CEOs See Opportunity Ahead"Pharma's future have never looked more promising -- or more ominous." That cautionary statement topping the front page of the last report in PWC's Pharma 2020 series could still stand today as a summary of the entire pharmaceuticals and life sciences industry.Read the rest of this entry »
PWC's most recent survey of the CEOs of 87 of the largest pharmaceutical companies found optimism about the growth of their individual revenues as well as ...
Pharma Unlikely to See Recovery This YearIn a bluntly worded economic recap for the pharmaceutical industry, Evaluate Pharma had this to say:Read the rest of this entry »
"If anything can be gleaned from the first half of 2016 it is that the peak is in the past. Any hopes that the declines of the second half of 2015 might be reversed must now be put to bed, and the highs of last July be consigned to the record books."
In its ...
Drug Companies Making Millions From Off-Label Use of Orphan DrugsCharging that orphan drugs "have become a lucrative business opportunity for pharmaceutical companies," a new report suggests drug makers are gaming a system intended to spur the development of treatments that would not otherwise be profitable.Read the rest of this entry »
Funded by the insurance lobby AHIP (American Health Insurance Plans), the report says pharmaceutical companies are benefiting from the tax advantages, market exclusivity and clinical subsidies provided by the Orphan Drug Act. But many ...
Future Looks Strong For Europe's PharmaEurope's economic outlook may be murky, but the future for pharmaceutical growth is rosy.Read the rest of this entry »
EvaluatePharma's latest whitepaper, "Pharmaceutical Innovation in Europe," says with potential blockbuster drugs already on the market or in the pipeline, pharma's revenue is forecast to grow at an annual compound rate of 3.2%, twice the GDP of the European market.
"Despite all the challenges posed by payers and the increasing scrutiny on ...
This Pill Will Make You SmarterWho doesn't want to be more alert, sharper, quicker with a better memory? A good night's sleep, exercise, nutrition and a cup of joe have all been shown to improve cognition. Some people -- students especially -- have tinkered with Ritalin and other similar drugs for a quick boost in brain ability, though researchers doubt they have much effect.Read the rest of this entry »
Now, though, a real-world "Limitless" pill may have been found. Two ...
Pharmaceutical Industry Faces Shortening of ExclusivityA new bill to cut the exclusivity period for new biologics by 5 years is getting some bipartisan support in Congress, which is giving its proponents hope that 2016 might be the year it passes.Read the rest of this entry »
Previous attempts to reduce the 12 year period in which a developer has the exclusive right to market and sell a biologic have failed to make it through Congress. Now, in the wake of public ...
Drug Price List Increases Lower This YearAfter a bruising year in which pharmaceutical companies came under attack for their drug pricing policies, indications are that this year price increases will be more modest.Read the rest of this entry »
Deutsche Bank analysts found the average industry increase was 5% through April. Last year, it was 7.8%.
Valeant is responsible for a good part of the lower increase. After hiking its list price by an industry-leading 25.8% in the first four ...